These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30348298)

  • 1. FGF23 blockade coming to clinical practice.
    Emma F; Haffner D
    Kidney Int; 2018 Nov; 94(5):846-848. PubMed ID: 30348298
    [No Abstract]   [Full Text] [Related]  

  • 2. [Inhitibion of FGF23 activities as a possible new treatment for patients with FGF23-related hypophosphatemic diseases].
    Kinoshita Y
    Clin Calcium; 2016 Feb; 26(2):233-9. PubMed ID: 26813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Burosumab Therapy for X-Linked Hypophosphatemia and Therapeutic Implications for CKD.
    Perwad F; Portale AA
    Clin J Am Soc Nephrol; 2019 Jul; 14(7):1097-1099. PubMed ID: 31171590
    [No Abstract]   [Full Text] [Related]  

  • 4. [Rickets/Osteomalacia. Anti-FGF23 antibody therapy in patients with FGF23-related hypophosphatemic rickets and osteomalacia.].
    Kinoshita Y
    Clin Calcium; 2018; 28(10):1373-1379. PubMed ID: 30269120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [FGF23-related hypophosphatemic rickets/osteomalacia].
    Ito N; Fukumoto S
    Clin Calcium; 2007 Oct; 17(10):1514-20. PubMed ID: 17906402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational analysis of patients with FGF23-related hypophosphatemic rickets.
    Kinoshita Y; Saito T; Shimizu Y; Hori M; Taguchi M; Igarashi T; Fukumoto S; Fujita T
    Eur J Endocrinol; 2012 Aug; 167(2):165-72. PubMed ID: 22577109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice.
    Aono Y; Hasegawa H; Yamazaki Y; Shimada T; Fujita T; Yamashita T; Fukumoto S
    J Bone Miner Res; 2011 Apr; 26(4):803-10. PubMed ID: 20939065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical aspect of recent progress in phosphate metabolism. The pathophysiology of diseases caused by aberrant actions of FGF23].
    Shimizu Y; Fukumoto S
    Clin Calcium; 2009 Jun; 19(6):802-7. PubMed ID: 19483274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [FGF23 related hypophosphatemic rickets:current therapy and unresolved issues].
    Harada D; Namba N
    Clin Calcium; 2016 Feb; 26(2):269-76. PubMed ID: 26813507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Burosumab: First Global Approval.
    Lamb YN
    Drugs; 2018 Apr; 78(6):707-714. PubMed ID: 29679282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment.
    Kinoshita Y; Fukumoto S
    Endocr Rev; 2018 Jun; 39(3):274-291. PubMed ID: 29381780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes of the lower limb deformity in children with FGF23-related hypophosphatemic rickets treated with Burosumab: a single-center prospective study.
    Sawamura K; Hamajima T; Izawa M; Kaneko H; Kitamura A; Kitoh H
    J Pediatr Orthop B; 2024 Jan; 33(1):90-96. PubMed ID: 36728857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Rickets/Osteomalacia. FGF23-related hypophosphatemic rickets/osteomalacia.].
    Fukumoto S
    Clin Calcium; 2018; 28(10):1313-1317. PubMed ID: 30269112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Fibroblast growth factor (FGF) 23 works as a phosphate-regulating hormone and is involved in the pathogenesis of several disorders of phosphate metabolism].
    Fukumoto S
    Rinsho Byori; 2007 Jun; 55(6):555-9. PubMed ID: 17657990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bone and joint diseases in children. Phosphaturic hormone, FGF23, and bone metabolism].
    Ozono K
    Clin Calcium; 2010 Jun; 20(6):896-903. PubMed ID: 20513948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two Case Reports of FGF23-Induced Hypophosphatemia in Childhood Biliary Atresia.
    Wasserman H; Ikomi C; Hafberg ET; Miethke AG; Bove KE; Backeljauw PF
    Pediatrics; 2016 Aug; 138(2):. PubMed ID: 27462066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical aspect of recent progress in phosphate metabolism. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23)].
    Endo I
    Clin Calcium; 2009 Jun; 19(6):815-20. PubMed ID: 19483276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-fibroblast growth factor 23 antibody therapy.
    Fukumoto S
    Curr Opin Nephrol Hypertens; 2014 Jul; 23(4):346-51. PubMed ID: 24848934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Rickets].
    Yasuda T
    Clin Calcium; 2009 Jan; 19(1):109-16. PubMed ID: 19122271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Burosumab Therapy in Children with X-Linked Hypophosphatemia.
    Carpenter TO; Whyte MP; Imel EA; Boot AM; Högler W; Linglart A; Padidela R; Van't Hoff W; Mao M; Chen CY; Skrinar A; Kakkis E; San Martin J; Portale AA
    N Engl J Med; 2018 May; 378(21):1987-1998. PubMed ID: 29791829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.